FinelliL., MillerJ.T., TokarsJ.I., AlterM.J., ArduinoM.J.National surveillance of dialysis-associated diseases in the United States, 2002.Semin Dial2005; 18: 52–61.
2.
JaiswalS.K., ChitnisD.S., SalgiaP., SepahaA., PanditC.S.Prevalence of hepatitis viruses among chronic renal failure patients on hemodialysis in Central India.Dial Transplant2002; 31: 234–40.
3.
GuhJ.Y., LaiV.H., YangC.Y.. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients.Nephron1995; 69: 459–65.
4.
MaisonneuveP., AgodoaL., GellerR.. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study.Lancet1999; 354: 93–9.
5.
Anonymous.The current state of chronic dialysis treatment in Japan (as of December 31, 2000).Therap Apher Dial2003; 7: 3–35.
6.
GoodkinD.A., Bragg-GreshamJ.L., KoenigK.G.. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The dialysis outcomes and practice patterns study (DOPPS).J Am Soc Nephrol2003; 14: 3270–7.
7.
MarcelliD., StanhardD., ConteF., HeldP.J., LocatelliF., PortF.K.ESRD patient mortality with adjustement for comorbid conditions in Lombardy (Italy) versus the United States.Kidney Int1996; 50: 1013–8.
8.
FabriziF., MartinP., DixitV., BunnapradistS., DulaiG.Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis.Aliment Pharmacol Ther2004; 20: 1271–7.
9.
Kalantar-ZadehK., McAllisterC., MillerL.G.Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study.Nephrol Dial Transplant2005; 20: 1662–9.
10.
OhS., AfdhalN.H.Antiviral therapy for treatment naive patients with hepatitis C virus.Gastroenterol Clin N Am2004; 33: 497–511.
11.
RussoM.W., GoldsbergC., JacobsonI.M., BrownR.S.Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety.Am J Gastroenterol2003; 98: 1610–5.
12.
FabriziF., DulaiG., DixitV., BunnapradistS., MartinP.Meta-analysis: Interferon for the treatment of chronic hepatitis C in dialysis patients.Aliment Pharmacol Ther2003; 18: 1071–81.
13.
ThevenotT., RegimbeauC., RatziouV., LeroyV., OpolonP., PoynardT.Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients.J Viral Hepat2001; 8: 48–62.
14.
McHutchisonJ.G., GordonS.C., SchiffE.R.. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.N Engl J Med1998; 339: 1485–92.
15.
BruchfeldA., StahleL., AnderssonJ., SchvarczR.Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection- a pilot study.J Viral Hepat2001; 8: 287–92.
16.
GuptaS.K., GlueP., JacobsS., BelleD., AffrimeM.Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects.Br J Clin Pharmacol2003; 56: 131–4.
17.
MartinP., MitraS., FarringtonK.. Pegylated (40KDA) interferon alfa-2A (Pegasys) is unaffected by renal impairment.Hepatology2000; 32: 842 [Abstract].
18.
AnnichiaricoB.E., SicilianoM.Pegylated interferon-alpha2b monotherapy for haemodialyis patients with chronic hepatitis C.Aliment Pharmacol Ther2004; 20: 123–7.
19.
TetaD., LuscherB.L., GonversJ.J., FrancioliP., PhanO., BurnierM.Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients.Nephrol Dial Transplant2005; 20: 991–3.
20.
RussoM.W., GhalibR., SigalS., JoshiV.Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C.Nephrol Dial Transplant2006; 21: 437–43.
21.
SporeaI., PopescuA., SirliR., GoleaO., TotoliciC., DanilaM., VernicC.Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis.World J Gastroenterol2006; 12: 4191–4.
22.
KokogluO., UcmakH., HosogluS.. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.J Gastroenterol Hepatol2006; 21: 575–80.
23.
MukherjeeS., GilroyR.K., McCashlandT.M., SchaferD.F.Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: A prospective cohort study.Transplant Proc2003; 35: 1478–9.
24.
BruchfeldA., LindahlK., ReichardO., CarlssonT., SchvarczR.Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.J Viral Hepat2006; 13: 316–21.
25.
ZylberbergH., NalpasB., CarnotF.. Severe evolution of chronic hepatitis C in renal transplantation: a case control study.Nephrol Dial Transplant2002; 17: 129–33.
26.
HanafusaT., IchikawaY., KishikawaH.. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years.Transplantation1998; 66: 471–6.
27.
MathurinP., MouquetC., PoynardT.. Impact of hepatitis B and C virus on kidney transplantation outcome.Hepatology1999; 29: 257–61.
28.
CruzadoJ.M., Gil-VernetS., ErcillaG.. Hepatitis C virus associated membranoproliferative glomerulonephritis in renal allografts.J Am Soc Nephrol1996; 7: 2469–75.
29.
BloomR.D., RaoV., WengF., GrossmanR.A., CohenD., MangeK.C.Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus.J Am Soc Nephrol2002; 13: 1374–80.
30.
RostaingL., IzopetJ., BaronE.. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients.Transplantation1995; 59: 1426–31.
31.
KamarN., ToupanceO., BuchlerM.. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis is sustained after renal transplantation.J Am Soc Nephrol2003; 14: 2092–8.
